« Previous
Next »
Titles
- Tax administration: IRS oversight of hospitals’ tax-exempt status : testimony before the Subcommittee on Oversight, Committee on Ways and Means, House of Representatives1
- Technical assistance brief: implementation of inflation-indexed rebates for Part B drugs1
- Technical considerations for medical devices with physiologic closed-loop control technology: guidance for industry and Food and Drug Administration staff1
- Technology assessment: Vaccine development : capabilities and challenges for addressing infectious diseases : report to congressional committees1
- Telehealth was critical for providing services to Medicare beneficiaries during the first year of the COVID-19 pandemic1
- Testing of glycerin, propylene glycol, maltitol solution, hydrogenated starch hydrolysate, sorbitol solution, and other high-risk drug components for diethylene glycol and ethylene glycol: guidance for industry1
- The Commonwealth Fund / National Opinion Research Center Survey of Retiree Health Benefits, 2005: a chartbook1
- The Food and Drug Administration needs to improve the premarket tobacco application review process for electronic nicotine delivery systems to protect public health1
- The Office of Refugee Resettlement’s incident reporting system is not effectively capturing data to assist its efforts to ensure the safety of minors in HHS custody1
- The Provider Relief Fund helped select nursing homes maintain services during the COVID-19 pandemic, but some found guidance difficult to use1
- The Strategic National Stockpile was not positioned to respond effectively to the COVID-19 pandemic1
- The clinic's tale: chasing FQHC status not for the faint-hearted1
- The consistently low percentage of Medicare enrollees receiving medication to treat their opioid use disorder remains a concern1
- The future of remote patient monitoring1
- The prohibition of distributing free samples of tobacco products1
- The risk of misuse and diversion of buprenorphine for opioid use disorder appears to be low in Medicare Part D1
- The risk of misuse and diversion of buprenorphine for opioid use disorder in Medicare Part D continues to appear low: 20221
- The vaccine industry: does it need a shot in the arm?1
- Tobacco products: principles for designing and conducting tobacco product perception and intention studies1
- Toolkit for calculating opioid levels and identifying patients at risk of misuse or overdose: R and SQL programming code1